GlassScriptPhysician profile
Jonathan W Martin
NPI 1790793529
$3,290.76
in general payments reported to CMS, 2019-2025
26 companies · $22.20 in 2025
The $22.20 reported for 2025 was less than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
See the full distribution for Neurology (Psychiatry & Neurology)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $333 · 2020: $248 · 2021: $128 · 2022: $464 · 2023: $1,110 · 2024: $986 · 2025: $22.20.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,116 · Education: $2.50.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,115.70 |
| Education | $2.50 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $951.69 | 2021-2024 | |
| Novartis Pharmaceuticals Corporation | $639.15 | 2019-2024 | |
| Genentech USA, INC. | $278.38 | 2023-2024 | Ocrevus, Enspryng |
| Sk Life Science, INC. | $204.79 | 2023-2024 | Xcopri |
| Allergan, INC. | $183.81 | 2019-2020 | |
| Janssen Pharmaceuticals, INC | $173.61 | 2022-2023 | Ponvory |
| Genzyme Corporation | $99.47 | 2019-2023 | |
| Genentech, INC. | $89.52 | 2024 | Enspryng, Ocrevus |
| Amgen INC. | $62.22 | 2024 | Uplizna |
| Pfizer INC. | $59.36 | 2023-2025 | |
| Sunovion Pharmaceuticals INC. | $54.60 | 2019 | |
| Mallinckrodt Hospital Products INC. | $53.95 | 2022-2024 | Acthar |
| Emd Serono, INC. | $50.79 | 2024 | |
| Lilly USA, LLC | $49.14 | 2019-2023 | Emgality, Reyvow |
| Acorda Therapeutics, INC | $47.89 | 2022-2023 | Inbrija |
Show all 26 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $42.89 | 2024 | Inspire |
| Teva Pharmaceuticals USA, INC. | $42.13 | 2023 | Austedo, Austedo Xr |
| Celgene Corporation | $29.23 | 2023 | |
| Csl Behring | $29.06 | 2024 | Hizentra |
| Lundbeck LLC | $25.98 | 2024 | Rexulti |
| Tg Therapeutics, INC. | $24.90 | 2024 | |
| Biogen, INC. | $23.82 | 2023 | Tysabri, Vumerity |
| Eisai INC. | $23.38 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $21.10 | 2021 | |
| Horizon Therapeutics Plc | $15.20 | 2023 | Uplizna |
| Livanova USA, INC. | $14.70 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jonathan Martin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.